About Tonix Pharma
Tonix Pharma is a company based in New York (United States) founded in 2007. Tonix Pharma has raised $4.45 million across 10 funding rounds from investors including NIH and Technology Partners. The company has 81 employees as of December 31, 2024. Tonix Pharma offers products and services including TNX-102 SL, TNX-1300, TNX-1500, TNX-801, and TNX-1800. Tonix Pharma operates in a competitive market with competitors including CareDx, PanTher Therapeutics, BioAge Labs, Eledon and Onconic Therapeutics, among others.
- Headquarter New York, United States
- Employees 81 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Tonix Pharmaceuticals Holding Corp.
-
Annual Revenue
$10.09 M (USD)29.94as on Dec 31, 2024
-
Net Profit
-$130.04 M (USD)-11.47as on Dec 31, 2024
-
EBITDA
-$74.32 M (USD)34.86as on Dec 31, 2024
-
Total Equity Funding
$4.45 M (USD)
in 10 rounds
-
Latest Funding Round
$15 M (USD), Post-IPO
Oct 25, 2022
-
Investors
NIH
& 1 more
-
Employee Count
81
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Tonix Pharma
Tonix Pharma is a publicly listed company on the NASDAQ with ticker symbol TNXP in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Tonix Pharma
Tonix Pharma offers a comprehensive portfolio of products and services, including TNX-102 SL, TNX-1300, TNX-1500, TNX-801, and TNX-1800.
Drug for fibromyalgia and related disorders.
Therapy for cocaine intoxication and overdose.
Antibody for organ transplant rejection.
Vaccine candidate for mpox and smallpox.
Vaccine for COVID-19 and related viruses.
Treatment for Prader-Willi syndrome.
People of Tonix Pharma
Unlock access to complete
Unlock access to complete
Funding Insights of Tonix Pharma
Tonix Pharma has successfully raised a total of $4.45M across 10 strategic funding rounds. The most recent funding activity was a Post-IPO round of $15 million completed in October 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Tonix Pharma
Tonix Pharma has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include NIH and Technology Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made in US life sciences and energy companies.
|
Locked | Locked | Locked | |
|
Drug discovery services are provided to the biopharma sector.
|
Locked | Locked | Locked |
Investor details for Tonix Pharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Tonix Pharma
Investment portfolio details for Tonix Pharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Tonix Pharma
Detailed financials for Tonix Pharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Tonix Pharma Comparisons
Peer comparison for Tonix Pharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Tonix Pharma
Tonix Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as CareDx, PanTher Therapeutics, BioAge Labs, Eledon and Onconic Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Medical solutions for transplant patients are developed and provided.
|
|
| Locked | Locked | Locked |
Drug delivery systems for inoperable solid tumors are developed.
|
|
| Locked | Locked | Locked |
Bioinformatics platform is provided for biomarkers and drug discovery.
|
|
| Locked | Locked | Locked |
Therapeutics for transplantation in autoimmune and neurodegenerative diseases are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for cancer and gastrointestinal diseases are developed.
|
Detailed competitors of Tonix Pharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Tonix Pharma
Complete news archive for Tonix Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Tonix Pharma
Tonix Pharma was founded in 2007 and raised its 1st funding round 3 years after it was founded.
Tonix Pharma is headquartered in New York, United States. It is registered at New York, New York, United States.
Tonix Pharma is a funded company, having raised a total of $4.45M across 10 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Tonix Pharma is 81.
Annual revenue of Tonix Pharma is $10.09M as on Dec 31, 2024.
Tonix Pharma was founded in 2007 and is headquartered in New York, United States. Medicines targeting central nervous system and immunological disorders are developed by the company within the pharmaceutical sector. Operations focus on advancing therapeutic candidates, including TNX-601 (tianeptine oxalate) for post-traumatic stress disorder treatment and TNX-801 involving horsepox virus. Research and development activities are conducted to address unmet medical needs in these areas.
Tonix Pharma's top competitors include CareDx, PanTher Therapeutics and BioAge Labs.
Tonix Pharma offers TNX-102 SL, TNX-1300, TNX-1500, TNX-801, and 2 more products and services.
Yes, Tonix Pharma is publicly traded on NASDAQ under the ticker symbol TNXP.
Tonix Pharma has 2 investors. Key investors include NIH, and Technology Partners.
The ticker symbol of Tonix Pharma is TNXP on NASDAQ.